On November 16, 2017, the Food and Drug Administration granted regular approval to obinutuzumab (GAZYVA, Genentech, Inc.)

When was Gazyva approved by the FDA?

On November 16, 2017, the US Food and Drug Administration (FDA) approved obinutuzumab (Gazyva; Genentech), an anti-CD20 monoclonal antibody, for the treatment of adults with untreated, stage II bulky, stage III, or stage IV follicular lymphoma, in combination with chemotherapy, followed by obinutuzumab monotherapy in ...

Is Gazyva chemo?

Gazyva™ is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Gazyva™ is classified as a "monoclonal antibody" (For more detail, see "How Gazyva™ Works" section below).